Your browser doesn't support javascript.
loading
Treating late-onset Tay Sachs disease: Brain delivery with a dual trojan horse protein.
Osher, Esther; Anis, Yossi; Singer-Shapiro, Ruth; Urshanski, Nataly; Unger, Tamar; Albeck, Shira; Bogin, Oren; Weisinger, Gary; Kohen, Fortune; Valevski, Avi; Fattal-Valevski, Aviva; Sagi, Liora; Weitman, Michal; Shenberger, Yulia; Sagiv, Nadav; Navon, Ruth; Wilchek, Meir; Stern, Naftali.
Afiliação
  • Osher E; The Sagol Center for Epigenetics and Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel.
  • Anis Y; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Singer-Shapiro R; The Sagol Center for Epigenetics and Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel.
  • Urshanski N; The Sagol Center for Epigenetics and Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel.
  • Unger T; The Sagol Center for Epigenetics and Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel.
  • Albeck S; Department of Structural Proteomics, Weizmann Institute of Science, Rehovot, Israel.
  • Bogin O; Department of Structural Proteomics, Weizmann Institute of Science, Rehovot, Israel.
  • Weisinger G; The Sagol Center for Epigenetics and Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel.
  • Kohen F; The Sagol Center for Epigenetics and Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel.
  • Valevski A; Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Fattal-Valevski A; Geha Mental Health Center, Petach-Tikva, Israel.
  • Sagi L; Pediatric Neurology Unit, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel.
  • Weitman M; Pediatric Neurology Unit, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel.
  • Shenberger Y; The Chemistry Department, Bar Ian University, Ramat Gan, Israel.
  • Sagiv N; The Chemistry Department, Bar Ian University, Ramat Gan, Israel.
  • Navon R; The Sagol Center for Epigenetics and Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel.
  • Wilchek M; Department of Human Molecular Genetics & Biochemistry, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Stern N; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
Mol Ther Methods Clin Dev ; 32(3): 101300, 2024 Sep 12.
Article em En | MEDLINE | ID: mdl-39211733
ABSTRACT
Tay-Sachs (TS) disease is a neurodegenerative disease resulting from mutations in the gene encoding the α-subunit (HEXA) of lysosomal ß-hexosaminidase A (HexA). We report that (1) recombinant HEXA alone increased HexA activity and decreased GM2 content in human TS glial cells and peripheral mononuclear blood cells; 2) a recombinant chimeric protein composed of HEXA linked to two blood-brain barrier (BBB) entry elements, a transferrin receptor binding sequence and granulocyte-colony stimulating factor, associates with HEXB in vitro; reaches human cultured TS cells lysosomes and mouse brain cells, especially neurons, in vivo; lowers GM2 in cultured human TS cells; lowers whole brain GM2 concentration by approximately 40% within 6 weeks, when injected intravenously (IV) to adult TS-mutant mice mimicking the slow course of late-onset TS; and increases forelimbs grip strength. Hence, a chimeric protein equipped with dual BBB entry elements can transport a large protein such as HEXA to the brain, decrease the accumulation of GM2, and improve muscle strength, thereby providing potential treatment for late-onset TS.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mol Ther Methods Clin Dev Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mol Ther Methods Clin Dev Ano de publicação: 2024 Tipo de documento: Article